Aldeyra Therapeutics (ALDX) Non Operating Interest Expenses (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Non Operating Interest Expenses for 14 consecutive years, with $23.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 100.0% year-over-year to $23.0; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (down 25.44% YoY), and the FY2025 full-year result was $1.9 million, down 1.09% from the prior year.
• Non Operating Interest Expenses retreated to $23.0 in Q2 2026 per ALDX's latest filing, from $468678.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $538743.0 in Q3 2023 and bottomed at $23.0 in Q2 2026.
• Historically, Non Operating Interest Expenses has averaged $448099.2 across 5 years, with a median of $475581.0 in 2025.
• The sharpest annual moves came in 2023 and 2026: Non Operating Interest Expenses climbed 29.22% in 2023, then plunged 100.0% in 2026.
• Over 5 years, Non Operating Interest Expenses stood at $460819.0 in 2022, then increased by 11.6% to $514264.0 in 2023, then retreated by 8.44% to $470863.0 in 2024, then increased by 0.93% to $475259.0 in 2025, then tumbled by 100.0% to $23.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $23.0, $468678.0, and $475259.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.